Email this article Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial
- Authors: Brose M.S.1, Worden F.P.2, Newbold K.L.3, Guo M.4, Hurria A.5
-
Affiliations:
- University of Pennsylvania.
- University of Michigan Health System.
- Royal Marsden Hospital
- Eisai.
- City of Hope
- Issue: Vol 8, No 2 (2018)
- Pages: 39-52
- Section: ORIGINAL REPORT
- Published: 07.07.2018
- URL: https://ogsh.abvpress.ru/jour/article/view/346
- DOI: https://doi.org/10.17650/2222-1468-2018-8-2-39-52
- ID: 346
Cite item
Full Text
Abstract
About the authors
M. S. Brose
University of Pennsylvania.
Author for correspondence.
Email: brosem@mail.med.upenn.edu
Philadelphia, PA United States
F. P. Worden
University of Michigan Health System.Ann Arbor, MI United States
K. L. Newbold
Royal Marsden HospitalLondon, UK United Kingdom
M. Guo
Eisai.Woodcliff Lake, NJ United States
A. Hurria
City of HopeDuarte, CA United States
References
Supplementary files
